The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of HER2/neu 655 genotyping in managing trastuzumab-induced cardiotoxicity risk in HER2-positive breast cancer patients.
 
Isabel Blancas
Honoraria - AstraZeneca Spain; Bristol Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Grunenthal; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte; Veracyte
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Veracyte
Research Funding - Agendia (Inst); AstraZeneca Spain (Inst); Lilly; Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Roche
Other Relationship - Fundación San Juan de Dios; Medical Science Innovation Research (MEDSIR)
 
Marta Legerén
Honoraria - Received honoraria as Medical Monitor from Medical Scienfia Innovation Research (MEDSIR). Additionally, received honoraria from AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Gilead, Grünenthal, GSK, Jazz Pharmaceutical, Lilly, MSD, No
Consulting or Advisory Role - Participated in advisory collaboration with AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Gilead, Grünenthal, GSK, Jazz Pharmaceutical, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, and Veracyte.
Research Funding - The institution received grants and research support from Agendia, AstraZeneca, Lilly, Pfizer, and Roche.
Travel, Accommodations, Expenses - Travel, accommodations, and meeting support were provided by AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer, Pierre-Fabre, and Roche.
 
Lidia Córdoba
Consulting or Advisory Role - Menarini
Speakers' Bureau - AstraZeneca Spain; Gilead Sciences; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis
 
Carlos Rodriguez Gonzalez
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Fernando Rodríguez-Serrano
No Relationships to Disclose